Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1812 • ACR Convergence 2020
Longitudinal Blood DNA Methylation in a Multi-ethnic Cohort of SLE Patients
Cristina Lanata¹, Joanne Nititham², Kim Taylor², Sharon Chung², Laura Trupin¹, Patricia Katz³, Maria Dall'Era⁴, Jinoos Yazdany¹, Marina Sirota¹, Lisa Barcellos⁵ and Lindsey Criswell⁶, ¹UCSF, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³University of California, San Francisco, Novato, CA, ⁴Division of Rheumatology, University of California, San Francisco, CA, ⁵UC Berkeley, Berkeley, CA, ⁶Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA
Background/Purpose: Cross-sectional studies have shown associations between DNA methylation differences in whole blood with Systemic Lupus Erythematosus (SLE) status and outcomes such as lupus nephritis.…
Abstract Number: 1828 • ACR Convergence 2020
Comprehensive Efficacy of Anifrolumab Across Organ Domains in Patients with Active SLE: Pooled Data from 2 Phase 3 Trials
Eric Morand¹, Richard Furie², Ian Bruce³, Ed Vital⁴, Maria Dall'Era⁵, Emmanuelle Maho⁶, Lilia Pineda⁷ and Raj Tummala⁷, ¹Monash University, Melbourne, Australia, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, ³Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Division of Rheumatology, University of California, San Francisco, CA, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁷BioPharmaceuticals R&D, AstraZeneca, Gaithersburg
Background/Purpose: SLE is a heterogeneous autoimmune disease with clinical manifestations across multiple organ systems. In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab treatment resulted…
Abstract Number: 1846 • ACR Convergence 2020
Evaluating the Risk of QT-prolongation Associated with Hydroxychloroquine Use with and Without Antidepressants in SLE Patients with Fibromyalgia
Jacinta Renaldi¹, Fotios Koumpouras¹ and Mei Xue Dong¹, ¹YALE SCHOOL OF MEDICINE, New Haven, CT
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease predominantly affecting woman of child-bearing age. Concurrent fibromyalgia syndrome (FMS) has been reported in…
Abstract Number: 0249 • ACR Convergence 2020
Validation of the SIMPLE Index for Disease Activity of Systemic Lupus Erythematosus in Chinese Patients
Chi Chiu Mok¹, Ling Yin Ho¹, Kar Li Chan² and Meenakshi Jolly³, ¹Tuen Mun Hospital, Hong Kong, China (People's Republic), ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Rush University, Chicago, IL
Background/Purpose: The SIMPLE (SIMple Disease Assessment for People with Lupus Erythematosus) index is a composite numeric tool that captures disease activity from patients’ self-assessment with…
Abstract Number: 0266 • ACR Convergence 2020
The Correlation Between Pregnancy, Disease Activity and Adverse Pregnancy Outcomesin Patients with Systemic Lupus Erythematosus
Cigdem Cetin¹, Tugba Sarac Sivrikoz¹, Muge Ates Tıkız¹, Ege Sinan Torun¹, Sibel Zarali¹, Yasemin Yalcinkaya¹, Ahmet Gül¹, Murat İnanç¹, Mahdume Lale Öcal², İbrahim Kalelioğlu¹ and Bahar Artim Esen¹, ¹İstanbul Faculty of Medicine, İstanbul, Turkey, ²Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey
Background/Purpose: Patients with systemic lupus erythematosus (SLE) can present with acute disease flares/exacerbations during pregnancy and postpartum period1. These flares can cause adverse pregnancy outcomes…
Abstract Number: 0282 • ACR Convergence 2020
Expression of the cGAMP Transporter SLC19A1 Is Altered in Systemic Lupus Erythematosus
Jeong Min Yu¹, Gantsetseg Tumurkhuu², Erica Montano², Gabriela de los Santos², Daniel J Wallace², Mariko Ishimori³ and Caroline Jefferies¹, ¹Cedars-Sinai Medical Center, West Hollywood, CA, ²Cedars-Sinai Medical Center, Los Angeles, ³Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Inappropriate sensing of nucleic acids leading to enhanced type I interferon (IFN) induction is a hallmark of SLE, contributing to breakdown of immune tolerance…
Abstract Number: 0300 • ACR Convergence 2020
Exposure to Topical Antimicrobials Reduces Inflammatory Gene Expression in Cutaneous Lupus Lesional Skin
Sirisha Sirobhushanam¹, Allison Billi², Alex Tsoi², Celine Berthier², Johann Gudjonsson³ and J. Michelle Kahlenberg⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Ann ArborUniversity of Michigan, ⁴Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Lupus lesional skin has elevated interferon expression, is highly colonized with Staphylococcus aureus (50%) and has no FDA-approved treatment options. S. aureus is known…
Abstract Number: 0495 • ACR Convergence 2020
Epstein Barr Virus (EBV), an Etiologic Factor for Systemic Lupus Erythematosus (SLE), Interacts with SLE Risk Loci Through EBV-encoded Transcription Co-factors (co-TFs)
Viktoryia Laurynenka¹, Xiaoting Chen¹, Sreeja Parameswaran¹, Shruti Eswar², Kenneth Kaufman³, Bahram Namjou⁴, Matthew Weirauch⁵, Leah Kottyan⁴ and John Harley⁶, ¹Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children’s Hospital Medical Center, Cincinnati, ³Cincinnati Children’s Hospital Medical Center;US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁴Cincinnati Children’s Hospital Medical Center/Univ of Cincinnati, Cincinnati, OH, ⁵Cincinnati Children’s Hospital Medical Center/Univ of Cincinnati, 535 Terrace Ave, ⁶Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: SLE affects millions worldwide. The etiology of this complex autoimmune disease is the consequence of both strong genetic and environmental components. Genome-wide association studies…
Abstract Number: 0616 • ACR Convergence 2020
Correlation Between Disease Activity and Perceived Economic Barriers to Care in a Population of African American Women with Systemic Lupus Erythematosus
Ashley White¹, Trevor Faith¹, Aissatou Ba¹, Viswanathan Ramakrishnan², Hetlena Johnson³, Jillian Rose⁴, Clara Dismuke-Greer⁵, Jim Oates⁶, Leonard Egede⁷ and Edith Williams¹, ¹Medical University of South Carolina, Charleston, SC, ²medical university of south carolina, south carolina, ³LupusCSC, Columbia, SC, ⁴Hospital for Special Surgery, New York, ⁵Palo Alto VA, Palo Alto, CA, ⁶Medical University of South Carolina, Charleston, SC, Charleston, SC, ⁷Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex, multifactorial disease with heterogeneous presentation. Disease activity – the number and severity of symptoms – can be…
Abstract Number: 0849 • ACR Convergence 2020
Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrated Analysis of Phase 2 and Phase 3 Trials
Joan Merrill¹, Kenneth Kalunian², Richard Furie³, Kevin Winthrop⁴, Patricia Primakov⁵, Lilia Pineda⁶, Gabriel Abreu⁷ and Raj Tummala⁶, ¹Oklahoma Medical Research Foundation, Oklahoma City, ²School of Health Sciences, University of California, La Jolla, ³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴Oregon Health & Science University, Portland, OR, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: In the phase 2 MUSE and phase 3 TULIP-1 and TULIP-2 trials, treatment with anifrolumab, a monoclonal antibody to the type I interferon receptor,…
Abstract Number: 0868 • ACR Convergence 2020
Impact of Proteinuria on the Clearance of Monoclonal Antibodies: Potential Clinical Implications
Justin Penzenstadler¹, Jianmeng Chen², Aaron Park², Rosemarie Neuner², Aliza Thompson², Lei He², Ping Ji², Nikolay Nikolov² and Chandrahas Sahajwalla², ¹FDA, F, ²FDA, Silver spring
Background/Purpose: In general, renal elimination is minimal for therapeutic proteins with a molecular weight more than 69 KDa. However, in patients with proteinuria, there is…
Abstract Number: 0984 • ACR Convergence 2020
Neighborhood Deprivation and Race/Ethnicity Affects COVID-19 Risk and Severity in SLE
Ashira Blazer¹, Ruth Fernandez-Ruiz², Mala Masson², Rebecca Haberman³, Rochelle Castillo⁴, Jose Scher⁴, Huda Algasas⁵, Allison Guttmann², Philip Carliucci³, Kristina Deonaraine², Michael Golpanian⁶, Kimberly Robins², Miao Chang², H. Michael Belmont⁶, Jill Buyon⁷, Amit Saxena³ and Peter Izmirly⁶, ¹NYU School of Medicine, New York, NY, ²New York University School of Medicine, New York, ³NEW YORK UNIVERSITY SCHOOL OF MEDICINE, New York, NY, ⁴NYU School of Medicine, New York City, ⁵Columbia University, New York, NY, ⁶New York University, New York, NY, ⁷Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Disparities have been reported during the coronavirus disease (COVID-19) outbreak. Systemic lupus erythematosus (SLE) patients represent a unique group that is affected by clinical,…
Abstract Number: 1089 • ACR Convergence 2020
Intermuscular Adipose Tissue in Patients with Systemic Lupus Erythematosus
Jorge Gamboa¹, Daniel Carranza Leon¹, Rachelle Crescenzi¹, Adriana Marton², Annette Oeser¹, Cecilia Chung¹, Jens Titze², Michelle Ormseth¹ and C. Michael Stein¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Duke NUS Medical School, Singapore, Singapore
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have reduced physical activity and frequently complain of fatigue. Exercise reduces fatigue in patients with SLE; however, the…
Abstract Number: 1265 • ACR Convergence 2020
2019 Lupus Classification Criteria Score Predicting Cost of Future Hospitalizations
Saurav Suman¹, Amna Batool², Joshua Keller² and William Neal Roberts², ¹University of Kentucky, Horseheads, NY, ²University of Kentucky, Lexington, KY
Background/Purpose: The latest 2019 Lupus Classification criteria score (CCS) is based on weighted criteria and has been shown to predict 10-year mortality1. Our previous study…
Abstract Number: 1281 • ACR Convergence 2020
Opioid-Related Encounters as a Predictor of 30-Day Readmissions in Lupus
Christie Bartels¹, Maria Schletzbaum², Yi Chen³ and Amy Kind⁴, ¹University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, ²University of Wisconsin-Madison School of Medicine and Public Health, Department of Population Health Sciences, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Department of Biostatistics and Medical Informatics, Madison, WI, ⁴University of Wisconsin-Madison School of Medicine and Public Health, Department of Medicine, Health Services and Care Research Program, Geriatrics Division, Madison, WI
Background/Purpose: One in four Medicare hospitalizations with systemic lupus erythematosus (SLE) results in readmission within 30 days, with “injuries and poisonings” as the second most…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].